PRKG1 and viral infectious disease: These findings, and additional findings from other cell lines and virus infections (El-Bacha et al, 2004; Munger et al, 2006) show that our overall findings are experimentally supported and that targets such as ENO, GAPD, PGM, and PGK, which involve in glycolysis and the entrance to the TCA cycle can be indeed promising drug targets for inhibiting SARS-CoV-2 replication in cells.